You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

Details for Patent: 8,557,993


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 8,557,993 protect, and when does it expire?

Patent 8,557,993 protects LIVALO and is included in one NDA.

Protection for LIVALO has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has thirty-six patent family members in nine countries.

Summary for Patent: 8,557,993
Title:Crystalline forms of pitavastatin calcium
Abstract: The present invention is directed to new crystalline forms of Pitavastatin hemicalcium salt, referred to hereinafter as polymorphic Forms A, B, C, D, E and F, as well as the amorphous form. Furthermore, the present invention is directed to processes for the preparation of these crystalline forms and the amorphous form and pharmaceutical compositions comprising these crystalline forms or the amorphous forms.
Inventor(s): Van der Schaaf; Paul Adriaan (Hagenthal-le-Haut, FR), Blatter; Fritz (Reinach, CH), Szelagiewicz; Martin (Muenchenstein, CH), Schoening; Kai-Uwe (Oberwil, CH)
Assignee: Nissan Chemical Industries Ltd. (Tokyo, JP)
Application Number:13/664,498
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,557,993
Patent Claim Types:
see list of patent claims
Compound; Process; Composition;

Drugs Protected by US Patent 8,557,993

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Kowa Co LIVALO pitavastatin calcium TABLET;ORAL 022363-001 Aug 3, 2009 AB RX Yes No ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Kowa Co LIVALO pitavastatin calcium TABLET;ORAL 022363-002 Aug 3, 2009 AB RX Yes No ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Kowa Co LIVALO pitavastatin calcium TABLET;ORAL 022363-003 Aug 3, 2009 AB RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,557,993

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
03405080Feb 12, 2003

International Family Members for US Patent 8,557,993

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2004212160 ⤷  Sign Up
Canada 2513837 ⤷  Sign Up
Canada 2785954 ⤷  Sign Up
China 100374422 ⤷  Sign Up
China 101219992 ⤷  Sign Up
China 102285916 ⤷  Sign Up
China 1747934 ⤷  Sign Up
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.